Theravance Biopharma (TBPH) Total Non-Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has reported Total Non-Current Liabilities for 14 consecutive years, with $472.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 37.91% year-over-year to $472.1 million; the TTM figure through Mar 2026 stood at $472.1 million (up 37.91% YoY), while the FY2025 annual figure was $485.3 million, up 79.42% from the prior year.
• Total Non-Current Liabilities eased to $472.1 million in Q1 2026 per TBPH's latest filing, from $485.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $700.8 million in Q3 2022 and bottomed at $270.5 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $418.0 million across 5 years, with a median of $405.9 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities plunged 43.07% — and 2025, when it soared 79.42%.
• Theravance Biopharma's Total Non-Current Liabilities stood at $531.4 million in 2022, then plunged by 43.07% to $302.5 million in 2023, then declined by 10.6% to $270.5 million in 2024, then surged by 79.42% to $485.3 million in 2025, then decreased by 2.72% to $472.1 million in 2026.
• Business Quant data shows TBPH's Total Non-Current Liabilities at $472.1 million in Q1 2026, $485.3 million in Q4 2025, and $415.1 million in Q3 2025.